The rapidly changing landscape around COVID-19 has left little time for federal enforcement actions. But that should shift as the vaccine becomes more widely used in coming months – and as it does, watch for products covered under the PREP Act, diagnostics, and emergency use authorization (EUA) products to come under scrutiny, a panel of attorneys recently said at a conference hosted by the Food and Drug Law Institute.
The Public Readiness and Preparedness (PREP) Act allows the secretary of the US Department of Health and Human Services (HHS)...